Durability and correlates of vaccine protection against Zika virus in rhesus monkeys

Peter Abbink; Rafael A. Larocca; Kittipos Visitsunthorn; Michael Boyd; Rafael A. De La Barrera; Gregory D. Gromowski; Marinela Kirilova; Rebecca Peterson; Zhenfeng Li; Ovini Nanayakkara; Ramya Nityanandam; Noe B. Mercado; Erica N. Borducchi; Abishek Chandrashekar; David Jetton; Shanell Mojta; Priya Gandhi; Jake Lesuer; Shreeya Khatiwada; Mark G. Lewis; Kayvon Modjarrad; Richard G. Jarman; Kenneth H. Eckels; Stephen J. Thomas; Nelson L. Michael; Dan H. Barouch

doi:10.1126/scitranslmed.aao4163

Durability and correlates of vaccine protection against Zika virus in rhesus monkeys

Peter Abbink, Rafael A. Larocca, Kittipos Visitsunthorn, Michael Boyd, Rafael A. De La Barrera, Gregory D. Gromowski, Marinela Kirilova, Rebecca Peterson, Zhenfeng Li, Ovini Nanayakkara, Ramya Nityanandam, Noe B. Mercado, Erica N. Borducchi, Abishek Chandrashekar, David Jetton, Shanell Mojta, Priya Gandhi, Jake Lesuer, Shreeya Khatiwada, Mark G. LewisKayvon Modjarrad, Richard G. Jarman, Kenneth H. Eckels, Stephen J. Thomas, Nelson L. Michael, Dan H. Barouch^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Abstract

An effective Zika virus (ZIKV) vaccine will require long-term durable protection. Several ZIKV vaccine candidates have demonstrated protective efficacy in nonhuman primates, but these studies have typically involved ZIKV challenge shortly after vaccination at peak immunity. We show that a single immunization with an adenovirus vector-based vaccine, as well as two immunizations with a purified inactivated virus vaccine, afforded robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination. In contrast, two immunizations with an optimized DNA vaccine, which provided complete protection at peak immunity, resulted in reduced protective efficacy at 1 year that was associated with declining neutralizing antibody titers to subprotective levels. These data define a microneutralization log titer of 2.0 to 2.1 as the threshold required for durable protection against ZIKV challenge in this model. Moreover, our findings demonstrate that protection against ZIKV challenge in rhesus monkeys is possible for at least 1 year with a single-shot vaccine.

Original language	English
Article number	aao4163
Journal	Science Translational Medicine
Volume	9
Issue number	420
DOIs	https://doi.org/10.1126/scitranslmed.aao4163
State	Published - 13 Dec 2017
Externally published	Yes

Access to Document

10.1126/scitranslmed.aao4163

Cite this

Abbink, P., Larocca, R. A., Visitsunthorn, K., Boyd, M., De La Barrera, R. A., Gromowski, G. D., Kirilova, M., Peterson, R., Li, Z., Nanayakkara, O., Nityanandam, R., Mercado, N. B., Borducchi, E. N., Chandrashekar, A., Jetton, D., Mojta, S., Gandhi, P., Lesuer, J., Khatiwada, S., ... Barouch, D. H. (2017). Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Science Translational Medicine, 9(420), Article aao4163. https://doi.org/10.1126/scitranslmed.aao4163

@article{cdd7e45ecd71418c92ce19aba640cc0b,

title = "Durability and correlates of vaccine protection against Zika virus in rhesus monkeys",

abstract = "An effective Zika virus (ZIKV) vaccine will require long-term durable protection. Several ZIKV vaccine candidates have demonstrated protective efficacy in nonhuman primates, but these studies have typically involved ZIKV challenge shortly after vaccination at peak immunity. We show that a single immunization with an adenovirus vector-based vaccine, as well as two immunizations with a purified inactivated virus vaccine, afforded robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination. In contrast, two immunizations with an optimized DNA vaccine, which provided complete protection at peak immunity, resulted in reduced protective efficacy at 1 year that was associated with declining neutralizing antibody titers to subprotective levels. These data define a microneutralization log titer of 2.0 to 2.1 as the threshold required for durable protection against ZIKV challenge in this model. Moreover, our findings demonstrate that protection against ZIKV challenge in rhesus monkeys is possible for at least 1 year with a single-shot vaccine.",

author = "Peter Abbink and Larocca, {Rafael A.} and Kittipos Visitsunthorn and Michael Boyd and {De La Barrera}, {Rafael A.} and Gromowski, {Gregory D.} and Marinela Kirilova and Rebecca Peterson and Zhenfeng Li and Ovini Nanayakkara and Ramya Nityanandam and Mercado, {Noe B.} and Borducchi, {Erica N.} and Abishek Chandrashekar and David Jetton and Shanell Mojta and Priya Gandhi and Jake Lesuer and Shreeya Khatiwada and Lewis, {Mark G.} and Kayvon Modjarrad and Jarman, {Richard G.} and Eckels, {Kenneth H.} and Thomas, {Stephen J.} and Michael, {Nelson L.} and Barouch, {Dan H.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2017, American Association for the Advancement of Science.",

year = "2017",

month = dec,

day = "13",

doi = "10.1126/scitranslmed.aao4163",

language = "English",

volume = "9",

journal = "Science Translational Medicine",

issn = "1946-6234",

number = "420",

}

Abbink, P, Larocca, RA, Visitsunthorn, K, Boyd, M, De La Barrera, RA, Gromowski, GD, Kirilova, M, Peterson, R, Li, Z, Nanayakkara, O, Nityanandam, R, Mercado, NB, Borducchi, EN, Chandrashekar, A, Jetton, D, Mojta, S, Gandhi, P, Lesuer, J, Khatiwada, S, Lewis, MG, Modjarrad, K, Jarman, RG, Eckels, KH, Thomas, SJ, Michael, NL & Barouch, DH 2017, 'Durability and correlates of vaccine protection against Zika virus in rhesus monkeys', Science Translational Medicine, vol. 9, no. 420, aao4163. https://doi.org/10.1126/scitranslmed.aao4163

TY - JOUR

T1 - Durability and correlates of vaccine protection against Zika virus in rhesus monkeys

AU - Abbink, Peter

AU - Larocca, Rafael A.

AU - Visitsunthorn, Kittipos

AU - Boyd, Michael

AU - De La Barrera, Rafael A.

AU - Gromowski, Gregory D.

AU - Kirilova, Marinela

AU - Peterson, Rebecca

AU - Li, Zhenfeng

AU - Nanayakkara, Ovini

AU - Nityanandam, Ramya

AU - Mercado, Noe B.

AU - Borducchi, Erica N.

AU - Chandrashekar, Abishek

AU - Jetton, David

AU - Mojta, Shanell

AU - Gandhi, Priya

AU - Lesuer, Jake

AU - Khatiwada, Shreeya

AU - Lewis, Mark G.

AU - Modjarrad, Kayvon

AU - Jarman, Richard G.

AU - Eckels, Kenneth H.

AU - Thomas, Stephen J.

AU - Michael, Nelson L.

AU - Barouch, Dan H.

PY - 2017/12/13

Y1 - 2017/12/13

N2 - An effective Zika virus (ZIKV) vaccine will require long-term durable protection. Several ZIKV vaccine candidates have demonstrated protective efficacy in nonhuman primates, but these studies have typically involved ZIKV challenge shortly after vaccination at peak immunity. We show that a single immunization with an adenovirus vector-based vaccine, as well as two immunizations with a purified inactivated virus vaccine, afforded robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination. In contrast, two immunizations with an optimized DNA vaccine, which provided complete protection at peak immunity, resulted in reduced protective efficacy at 1 year that was associated with declining neutralizing antibody titers to subprotective levels. These data define a microneutralization log titer of 2.0 to 2.1 as the threshold required for durable protection against ZIKV challenge in this model. Moreover, our findings demonstrate that protection against ZIKV challenge in rhesus monkeys is possible for at least 1 year with a single-shot vaccine.

AB - An effective Zika virus (ZIKV) vaccine will require long-term durable protection. Several ZIKV vaccine candidates have demonstrated protective efficacy in nonhuman primates, but these studies have typically involved ZIKV challenge shortly after vaccination at peak immunity. We show that a single immunization with an adenovirus vector-based vaccine, as well as two immunizations with a purified inactivated virus vaccine, afforded robust protection against ZIKV challenge in rhesus monkeys at 1 year after vaccination. In contrast, two immunizations with an optimized DNA vaccine, which provided complete protection at peak immunity, resulted in reduced protective efficacy at 1 year that was associated with declining neutralizing antibody titers to subprotective levels. These data define a microneutralization log titer of 2.0 to 2.1 as the threshold required for durable protection against ZIKV challenge in this model. Moreover, our findings demonstrate that protection against ZIKV challenge in rhesus monkeys is possible for at least 1 year with a single-shot vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85038433757&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aao4163

DO - 10.1126/scitranslmed.aao4163

M3 - Article

C2 - 29237759

AN - SCOPUS:85038433757

SN - 1946-6234

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 420

M1 - aao4163

ER -

Durability and correlates of vaccine protection against Zika virus in rhesus monkeys

Abstract

Access to Document

Fingerprint

Cite this